Geron Corp (GERN): Total Liabilities
$344.67M
As of 2025-12-31
$300.39M
As of 2026-06-30
+46.1%
3-year compound annual growth
+42.0%
5-year compound annual growth
| Period ended | Total Liabilities | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $344.67M | +10.0% | 2026-03-02, Balance as of period end |
| 2024-12-31 | $313.46M | +114.5% | 2026-03-02, Balance as of period end |
| 2023-12-31 | $146.13M | +32.1% | 2025-02-27, Balance as of period end |
| 2022-12-31 | $110.58M | +11.0% | 2024-02-28, Balance as of period end |
| 2021-12-31 | $99.62M | +66.6% | 2023-03-16, Balance as of period end |
| 2020-12-31 | $59.78M | +96.9% | 2022-03-10, Balance as of period end |
| 2019-12-31 | $30.36M | n/a | 2021-03-11, Balance as of period end |
Total Liabilities at similar companies
| Company | Year ended | Total Liabilities | Change YoY |
|---|---|---|---|
| Geron Corp (GERN) | 2025-12-31 | $344.67M | +10.0% |
| Standard Biotools Inc. (LAB) | 2025-12-31 | $143.46M | +2.0% |
| Edgewise Therapeutics, Inc. (EWTX) | 2025-12-31 | $30.35M | +9.9% |
| Nuvation Bio Inc. (NUVB) | 2025-12-31 | $289.11M | +276.3% |
| Septerna, Inc. (SEPN) | 2025-12-31 | $214.26M | +486.9% |
| Organogenesis Holdings Inc. (ORGO) | 2025-12-31 | $164.81M | +46.4% |
| Travere Therapeutics, Inc. (TVTX) | 2025-12-31 | $490.36M | -8.4% |
| Olema Pharmaceuticals, Inc. (OLMA) | 2025-12-31 | $54.87M | +30.6% |
| Dianthus Therapeutics, Inc. (DNTH) | 2025-12-31 | $37.52M | +74.3% |
Compare GERN, LAB, EWTX, NUVB side by side · Screen every company in Pharmaceutical Preparations ↗